MCV4
/ Chongqing Zhifei
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2024
Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years
(clinicaltrials.gov)
- P3 | N=2450 | Active, not recruiting | Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
New P3 trial • Infectious Disease • Meningococcal Infections
1 to 1
Of
1
Go to page
1